
CLAIMS

What is claimed is:

1) A composition comprising, a plurality of silica particles that each have a surface and pores and that have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g; and a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof coated in the pores or on the surface of the silica particles.

2) The composition of claim 1 wherein the silica is hydrophilic fumed silica.

3) The composition of claim 1 or 2 wherein the silica particles have a mean grain diameter of 20-40 micron.

4) The composition of any one of claims 1-3 wherein the silica particles have a BET surface area of at least 150 m^2/g.


5) The composition of any one of claims 1-4 wherein the weight percentage of the compound of formula (I) to the silica particles is 50% ± 10%.

6) The composition of any one of claims 1 to 5 which is a pharmaceutical composition that further comprises one or more pharmaceutically acceptable excipients.

7) The composition of claim 6 which is formulated for oral administration.


8) The composition of claim 7 which is a tablet.

9) The composition of any one of claims1-8 wherein the compound of formula (I) has an enriched concentration of 99 ± 1% of the stereoisomer of formula (Ia):



(Ia)

10) A method comprising combining the compound of formula (I):



(I)

a suitable solvent, and a plurality of silica particles that each have a surface and pores, and that have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g, to provide a mixture, wherein the compound of formula (I) is coated in the pores and on the surface of the silica particles.

11) The method of claim 10 wherein the silica particles are hydrophilic fumed silica.

12) The method of claims 10 or 11 wherein the silica particles have a mean grain diameter of 20-40 micron.

13) The method of any one of claims 10-12 wherein the silica particles have a BET surface area of at least 150 m^2/g.


14) The method of any one of claims 10-13 wherein the weight of the compound of formula (I) divided by the weight of the silica particles is 1.0 ± 0.5.

15) The method of any one of claims 10-14 wherein the solvent is a (C_1-C_6) alcohol.

16) The method of any one of claims 10-14 wherein the solvent comprises ethanol.

17) A product prepared by the method described in any one of claims 10-16.

18) A tablet comprising: 1) a compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof and 2) a plurality of silica particles that each have a surface and pores, and that have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g, wherein the compound of formula (I) is coated in the pores and on the surface of the silica particles.

19) The tablet of claim 18 that further comprises another therapeutic agent.

20) The tablet of claim 18 that further comprises 3) microcrystalline cellulose; 4) hydroxypropyl cellulose; 5) croscarmellose sodium; and 6) magnesium stearate.

21) The tablet of any one of claims 18-20 wherein the compound of formula (I) has an enriched concentration of 99 ± 1% of the stereoisomer of formula (Ia):



22) The tablet of any one of claims 19-21 which comprises about 10 mg of the compound of formula (I); about 115 mg of the silica particles; about 151 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

23) The tablet of any one of claims 19-21 which comprises about 25 mg of the compound of formula (I); about 115 mg of the silica particles; about 136 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

24) The tablet of any one of claims 19-21which comprises about 100 mg of the compound of formula (I); about 115 mg of the silica particles; about 61 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

25) A pharmaceutical composition that comprise a plurality of silica particles that each have a surface and pores, and that have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g; a compound of formula (Ia); tenofovir disoproxil fumarate; emtricitabine; and elvitegravir, wherein the compound of formula (I) is coated in the pores and on the surface of the silica particles.

26) The composition of claim 25 wherein the silica is hydrophilic fumed silica.

27) The composition of any one of claims 25-26 wherein the silica particles have a mean grain diameter of 20-40 micron.

28) The composition of any one of claims 25-27 wherein the silica particles have a BET surface area of at least 150 m^2/g.

29) The composition of any one of claims 25-28 wherein the ratio of the weight of the compound of formula (I) to the weight of the silica particles is $1 \pm 0.05\%$.

30) The composition of claim 25 which is formulated for oral administration.


31) The composition of claim 30 which is formulated as a tablet.

32) A composition or method as described herein.

CLAIMS

What is claimed is:

1) A composition comprising, a plurality of solid silicon dioxide carrier particles; and a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof on or within the solid silicon dioxide carrier particles.

2) The composition of claim 1 wherein compressibility of the composition is greater than the compressibility of the plurality of solid carrier particles.

3) The composition of claim 1 wherein the hygroscopicity of the silicon dioxide carrier particles and the compound is higher than the hygroscopicity of the compound/silicon dioxide carrier particles mixture.

4) The composition of claim 1 wherein the plurality of solid silicon dioxide carrier particles have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g.

5) The composition of claim 3 wherein the silicon dioxide particles are hydrophilic fumed silica.

6) The composition of any one of claims 4-5 wherein the silica particles have a mean grain diameter of 20-40 micron.

7) The composition of any one of claims 4-6 wherein the silica particles have a BET surface area of at least 150 m^2/g.

8) The composition of any one of claims 4-6 wherein the compound of formula (I) is coated in the pores and/or on a surface of the silica particles.


9) The composition of any one of claims 1-6 wherein the weight percentage of the compound of formula (I) to the solid carrier particles is 50% ± 10%.

10) The composition of any one of claims 1 to 10 which is a pharmaceutical composition that further comprises one or more pharmaceutically acceptable excipients.

11) The composition of claim 10 which is formulated for oral administration.

12) The composition of claim 11 which is a tablet.


13) The composition of any one of claims 1-12 wherein the compound of formula (I) has an enriched concentration of 99 ± 1% of the stereoisomer of formula (Ia):



(Ia)

14) The composition of claim 13, comprising 150 mg ± 10% of the compound of formula (Ia).

15) A method comprising combining the compound of formula (I):



(I)

a suitable solvent, and a plurality of solid silicon dioxide carrier particles to provide a mixture.

16) The method of claim 15 wherein compressibility of the mixture is greater than the compressibility of the plurality of solid carrier particles.

17) The method of claim 15 wherein the hygroscopicity of the silicon dioxide carrier particles and the compound is higher than the hygroscopicity of the compound/silicon dioxide carrier particles mixture.

18) The method of claim 15 wherein the plurality of solid silicon dioxide carrier have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g.

19) The method of claim 18 wherein the silicon dioxide particles are hydrophilic fumed silica.

20) The method of claims 18 or 19 wherein the silica particles have a mean grain diameter of 20-40 micron.

21) The method of any one of claims 18-20 wherein the silica particles have a BET surface area of at least 150 m^2/g.


22) The method of any one of claims 18-21 wherein the weight of the compound of formula (I) divided by the weight of the silica particles is 1.0 ± 0.5.

23) The method of any one of claims 18-22 wherein the solvent is a (C_1-C_6) alcohol.

24) The method of any one of claims 18-22 wherein the solvent comprises ethanol.

25) A product prepared by the method described in any one of claims 15-24.

26) A tablet comprising: 1) a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof and 2) a plurality of solid silicon dioxide carrier particles.

27) The tablet of claim 26 wherein compressibility of the tablet is greater than the compressibility of the plurality of solid carrier particles.


28) The tablet of claim 26 wherein the hygroscopicity of the silicon dioxide carrier particles and the compound is higher than the hygroscopicity of the compound/silicon dioxide carrier particles mixture.

29) The tablet of claim 26 wherein the plurality of solid silicon dioxide carrier particles have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g.

30) The tablet of any one of claim 26 to 29 that further comprises another therapeutic agent.

31) The tablet of claim 26 that further comprises 3) microcrystalline cellulose; 4) hydroxypropyl cellulose; 5) croscarmellose sodium; and 6) magnesium stearate.

32) The tablet of any one of claims 26-31 wherein the compound of formula (I) has an enriched concentration of 99 ± 1% of the stereoisomer of formula (Ia):




(Ia)

33) The tablet of any one of claims 29-32which comprises about 10 mg of the compound of formula (I); about 115 mg of the silica particles; about 151 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

34) The tablet of any one of claims 29-32 which comprises about 25 mg of the compound of formula (I); about 115 mg of the silica particles; about 136 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

35) The tablet of any one of claims 29-32 which comprises about 100 mg of the compound of formula (I); about 115 mg of the silica particles; about 61 mg microcrystalline cellulose; about 6 mg hydroxypropyl cellulose; about 15 mg croscarmellose sodium; and about 3 mg magnesium stearate.

36) A pharmaceutical composition that comprises a plurality of solid silicon dioxide carrier particles; a compound of formula (Ia):



(Ia)

at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, non-nucleoside inhibitors of HCV, CCR5 inhibitors, and combinations thereof, and a pharmaceutically acceptable excipient.

37) The pharmaceutical composition of claim 36, wherein the additional therapeutic agent is darunavir.

38) The pharmaceutical composition of claim 36, wherein the additional therapeutic agent is atazanavir.

39) The pharmaceutical composition of claim 36 wherein compressibility of the composition is greater than the compressibility of the plurality of solid carrier particles.

40) The pharmaceutical composition of claim 36 wherein the hygroscopicity of the silicon dioxide carrier particles and the compound is higher than the hygroscopicity of the compound/silicon dioxide carrier particles mixture.

41) The pharmaceutical composition of claim 36, wherein the additional therapeutic agent is emtricitabine.

42) The pharmaceutical composition of claim 36, wherein the additional therapeutic agent is tenofovir disoproxil fumarate.

43) The pharmaceutical composition of claim 36, wherein the additional therapeutic agent is elvitegravir.

44) The pharmaceutical composition of claim 36 comprising a ternary combination of the compound of Formula (Ia)/ tenofovir disoproxil fumarate/ emtricitabine.

45) The pharmaceutical composition of claim 36 comprising a ternary combination of the compound of Formula (Ia)/ tenofovir disoproxil fumarate/ elvitegravir.

46) The pharmaceutical composition of claim 36 comprising a ternary combination of the compound of Formula (Ia)/ emtricitabine/ elvitegravir.

47) The pharmaceutical composition of claim 36 comprising a quaternary combination of the compound of Formula (Ia)/ tenofovir disoproxil fumarate/ emtricitabine/ elvitegravir.

48) The pharmaceutical composition of any one of claims 36-47 wherein the plurality of solid silicon dioxide carrier particles have a mean particle diameter of about 10 to about 120 micron and a BET surface area of about 40 to about 400 m^2/g.

49) The composition of claim 45 wherein the silicon dioxide particles are hydrophilic fumed silica.

50) The composition of any one of claims 36-49 wherein the silica particles have a mean grain diameter of 20-40 micron.

51) The composition of any one of claims 36-50 wherein the silica particles have a BET surface area of at least 150 m^2/g.

52) The composition of any one of claims 36-51 wherein the compound of formula (Ia) is coated in pores and/or on a surface of the silica particles.

53) The composition of any one of claims 36-52 wherein the ratio of the weight of the compound of formula (Ia) to the weight of the silica particles is $1 \pm 0.05\%$.

54) The composition of any one of claims 36-53 which is formulated for oral administration.

55) The composition of claim 54 which is formulated as a tablet.